Abstract: This invention relates to pharmaceutical combinations of a prostaglandin agonist and a HMG-CoA reductase inhibitor, methods of using such combinations and kits containing such combinations. The pharmaceutical combinations, methods and kits are useful to enhance bone formation in mammals, including humans.
Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.
Type:
Grant
Filed:
October 22, 1998
Date of Patent:
October 15, 2002
Assignee:
Surmodics, Inc.
Inventors:
Patrick E. Guire, Aron B. Anderson, Richard A. Amos, Terrence P. Everson
Abstract: The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by an ether group. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.
Abstract: This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.
Type:
Grant
Filed:
October 5, 2001
Date of Patent:
October 1, 2002
Assignee:
The Brigham and Women's Hospital
Inventors:
James L. Madara, Charles N. Serhan, Sean P. Colgan
Abstract: Many human conditions, often skin conditions, are treated topically or orally with a retinoid such as retinoic acid or acetretin, which treatment often has the side effect of dry, irritated, and/or peeling skin. The use of soaps, detergents, chemical irritants, and such can also cause these same side effects. These side effects can be reduced or eliminated by the topical administration of an inhibitor, especially a natural inhibitor, of the epidermal growth factor receptor (EGFR), administered concomitantly with the retinoid, separately from the retinoid (such as on an as needed basis), or both. Administration of the two together is facilitated by a composition suitable for topical application and comprising both the retinoid and a natural EGFR inhibitor. Preferred natural inhibitors are genistein and other isoflavones extracted from natural occurring substances, or simple derivatives of such substances.
Type:
Application
Filed:
February 27, 2002
Publication date:
September 26, 2002
Inventors:
Sewon Kang, Gray J. Fisher, John J. Voorhees
Abstract: A method for decreasing the inflammation associated with a chronic inflammatory intestinal condition in a patient is provided wherein the patient is administered an effective amount of a differentiating agent.
Abstract: A method of treating pain by the co-administration of an antidepressant together with one or more precursors or inducers of neurotransmitters, particularly amino acids selected from L-phenylalanine, L-tyrosine, L-tryptophan and L-DOPA.
Type:
Grant
Filed:
January 4, 2000
Date of Patent:
September 17, 2002
Assignee:
The WWK Trust of 225-235 High Street
Inventors:
David Frederick Horrobin, Cari Loder, Graham Cooper
Abstract: A method for reducing the average number of insemination administrations per herd comprising the step of administering to the herd native or extended semen with a simultaneous or sequential administration of prostaglandin is provided. Also provided is a novel composition of matter which includes either native semen, extended semen or a semen extender, one or more prostaglandins and one or more antibioitics.
Abstract: Disclosed is an inhibitor of replicative senescence of human keratinocytes containing retinoic acid, including all-trans retinoic acid, 3,4-didehydroretinoic acid, and 9-cis retinoic acid, as active ingredients. The retinoic acid plays an important role in extending the in vitro life span and inhibiting replicative senescence of the human mucosal keratinocytes and the human epidermal keratinocyes, thereby being used for a prophylactic or therapeutic agent of various diseases attributed to replicative senescence of the human oral keratinocytes. In addition, the inhibitor containing the retinoic acid can be used for a cosmetic purpose and as a prophylactic or therapeutic agent for wound-caused dermatitis and ski senescence.
Abstract: Methods and compositions for treating various disorders by administering a therapeutically effective amount of a retinoic acid receptor antagonist alone or in combination or in conjunction with other therapeutic agents to promote angiogenesis are provided. Also provided are methods for obtaining additional retinoic acid receptor antagonists for use as therapeutic agents to promote angiogenesis.
Abstract: A method for improving the integrity of the corneal epithelium by introducing into the eye an effective amount of a ophthalmically compatible retinoid sufficient to enhance the integrity of the corneal epithelium.
Type:
Application
Filed:
December 17, 2001
Publication date:
August 22, 2002
Inventors:
Andrea M. Lever, Richard V. Smerbeck, O. William Lever, Joseph C. Salamone
Abstract: This invention relates to pharmaceutical combinations of a prostaglandin agonist and a HMG-CoA reductase inhibitor, methods of using such combinations and kits containing such combinations. The pharmaceutical combinations, methods and kits are useful to enhance bone formation in mammals, including humans.
Abstract: In accordance with the present invention, it has been discovered that retinoic acid receptor (RAR) antagonists are capable of modulating processes mediated by other members of the steroid/thyroid hormone receptor superfamily, including permissive receptors such as PPARs (e.g., PPAR&agr;, PPAR&dgr; and PPAR&ggr;). Indeed, it has been discovered that RAR antagonists, in combination with agonists for members of the steroid/thyroid hormone receptor superfamily, are capable of inducing and/or enhancing processes mediated by such members.
Type:
Grant
Filed:
July 13, 1999
Date of Patent:
August 20, 2002
Assignee:
The Salk Institute for Biological Studies
Inventors:
Ronald M. Evans, Peter J. Tontonoz, Laszlo Nagy
Abstract: A cosmetic composition containing a retinoid and having an improved stability and mildness. Especially preferred compositions also include retinoid boosters and a polyhydric alcohol humectant.
Type:
Application
Filed:
November 1, 2001
Publication date:
August 15, 2002
Inventors:
Prem Chandar, Quynh T. Pham, Tak Yu Lam, Yan Zhou, Ritu Verma, Alexander Lips
Abstract: Combinations of a prostaglandin or an opthalmologically acceptable salt thereof and a topical carbonic anhydrase inhibitor or an opthalmologically acceptable salt thereof are particularly useful in the treatment of ocular hypertension and glaucoma. The combinations are characterized by an improved effect and reduced side-effects.
Type:
Application
Filed:
December 17, 2001
Publication date:
July 18, 2002
Applicant:
Merck & Co., Inc.
Inventors:
Gerald S. Ponticello, Michael F. Sugrue
Abstract: This invention relates to compositions and methods for the specific inhibition of neurotransmission. More specifically, the invention relates to isolated modified &agr;-bungarotoxin molecules that show high specificity for nicotinic acetylcholine receptors. Such modified &agr;-bungarotoxin molecules, as well as native &agr;-bungarotoxin molecules, are useful in a variety of conditions where localized inhibition of neuronal and/or muscle cell function is desirable.
Abstract: Methods of treatment of benign prostatic hyperplasia and reduction of the level of the prostate specific antigen (PSA) of benign prostate conditions are disclosed. The treatment method includes an initial treatment of patients with orally administration of an initial dosage of about 40 mg 13 cis-retinoic acid daily for a period from about ten days to about twenty days, and followed by a sustaining treatment of the patients with orally administration of a sustaining dosage of about 40 mg 13 cis-retinoic acid about every five to seven days in a sustaining period.
Abstract: Retinoid compounds which act specifically or selectively on RAR&agr; receptor subtypes in preference over RAR&bgr; and RAR&Ggr; receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
Type:
Application
Filed:
November 29, 2001
Publication date:
June 20, 2002
Applicant:
Allergan Sales, Inc.
Inventors:
Min Teng, Tien T. Duong, Roshantha A. Chandraratna
Abstract: Treatment with a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmnune diseases.
Type:
Grant
Filed:
January 21, 2000
Date of Patent:
June 18, 2002
Assignee:
G.D. Searle & Co.
Inventors:
Susan A Gregory, Peter C Isakson, Gary Anderson
Abstract: Methods and compositions of matter are described for treatment of inflammatory autoimmune and other diseases by administration of lipid fractions of sea cucumber tissue. Compositions of matter useful for inclusion in aquatic and human diets are also disclosed.
Abstract: Cold storage solutions for the preservation of organs and biological tissues prior to implantation, including a prostaglandin having vasodilatory, membrane stabilizing, platelet aggregation prevention upon reperfusion, and complement activation inhibitory properties, a nitric oxide donor, and a glutathione-forming agent.
Type:
Application
Filed:
October 12, 2001
Publication date:
May 30, 2002
Applicant:
Pike Laboratories, Inc.
Inventors:
Maximilian Polyak, Ben O?apos;Mar Arrington
Abstract: Mesomorphic complexes of vitamin A acid and cationic polyelectrolytes, their preparation and use. The cationic polyelectrolyte, for example PDADMAC, PM4VP, poly (ionene-6,3), polyethyleneimine or a poly-L-amino acid, is mixed with vitamin A acid to produce mesomorphic complexes. Uses of these mesomorphic complexes include the transport of vitamin A in the human body, the treatment of severe cases of acne externally, courses of skin rejuvenation, and the inhibition of malignant tumors.
Type:
Grant
Filed:
January 27, 2000
Date of Patent:
May 28, 2002
Assignee:
Max-Planck-Gesellschaft zur Förderung der
Weissenschaften e.V.
Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
Type:
Grant
Filed:
February 23, 1999
Date of Patent:
May 28, 2002
Assignee:
MCW Research Foundation
Inventors:
Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.
Type:
Application
Filed:
January 18, 2002
Publication date:
May 23, 2002
Inventors:
Gustavo C. Rodriguez, Regina Salas Whitaker
Abstract: The invention provides pharmaceutical formulations and methods for the treatment of individuals suffering from a condition, disease, or disorder that is treatable by the inhibition of angiogenesis. The compositions comprise a Golgi apparatus disturbing agent in a substantially nontoxic amount effective to inhibit angiogenesis in a patient in need of anti-angiogenesis therapy, a solvent, and a pharmaceutically acceptable carrier. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A.
Abstract: Plant sterols have been shown to be cholesterol-reducing agents in human serum. In the present invention, plant sterols, plant stanols, plant sterol esters and other non-toxic sterols are micromilled with emulsifiers in a solvent (water or edible oil) to produce dispersion which can be incorporated into full-fat, reduced-fat, low-fat, fat-free and triglyceride-free food products. Such water-based or edible oil-based dispersions can be used to incorporate relatively high levels of such sterols/stanols in food products without the adverse organoleptic effect normally associated with the use of such plant sterols and plant stanols.
Type:
Grant
Filed:
April 6, 2000
Date of Patent:
May 21, 2002
Assignee:
Kraft Foods, Inc.
Inventors:
Richard B. Rogers, John B. Topinka, Elizabeth Gwartney, Johnny Casanovas, Scott T. Ostergaard, Daniel G. Lis, John A. DeWalt, Anilkumar G. Gaonkar
Abstract: The present invention provides a method for treating or preventing the onset of Alzheimer's Disease comprising administering to a mammal in need thereof an Alzheimer's Disease-preventing or treating amount of a plasma-triglyceride level-lowering agent. Optionally, the plasma-triglyceride level-lowering agent can be co-administered with a cholesterol level-lowering agent.
Type:
Application
Filed:
June 26, 2001
Publication date:
May 9, 2002
Inventors:
Charles Larry Bisgaier, Mark Richard Emmerling, Alex Eugene Roher
Abstract: The present invention relates to a method to treat certain ocular complications, comprising the administration of an effective amount of a FAD to a patient in need of such treatment.
Type:
Application
Filed:
July 17, 2001
Publication date:
May 2, 2002
Inventors:
Christine Percicot, George N. Lambrou, Leopold Schmetterer
Abstract: The present invention relates to a use, in cosmetic preparations, of prostaglandin EP-2 and/or EP-4 receptor antagonists to attenuate, reduce or stop the growth of head hair and other hairs, and to the cosmetic treatment process using these compositions.
Type:
Application
Filed:
July 30, 2001
Publication date:
May 2, 2002
Inventors:
Bruno Bernard, Jean Francois Michelet, Yann Mahe
Abstract: The current invention is directed to methods of treating or preventing emphysema, pharmaceutical compositions suitable for the treatment or prevention of emphysema and methods for delivering formulations into the lung of a mammal suffering from emphysema.
Abstract: Compositions and methods are provided for ameliorating various effects of UVA and UVB radiation from the sun. The compositions including an ingredient that prevents photoaging from MED and subMED radiation, such as a retinoid, certain other compounds (such as N-acetylcysteine, 2-furildioxime, and vitamin C) and optionally other MMP inhibitors such as tetracyclines and/or compounds that inhibit the P-450-mediated metabolism of retinoids such as ketoconazole and other azole compounds. In the method, the composition is applied prior to exposure to the sun; depending upon the ingredients used in the composition, application should be from 7 to 48 hours prior to exposure. Compounds that prevent erythema (skin reddening, sunburn) do not necessarily protect against UV-mediated elevation of MMP levels and activity, and similarly compounds that prevent UV-mediated elevation of MMP levels and activity are not necessarily effective against UV-induced erythema.
Type:
Grant
Filed:
July 13, 2000
Date of Patent:
April 2, 2002
Assignee:
Regents of the University of Michigan
Inventors:
Gary J. Fisher, John J. Voorhees, Sewon Kang
Abstract: Vasoactive compounds are described for the treatment of erectile dysfunction and impotence. The compounds are reaction products of an anionic or negatively charged vasoactive or erection-inducing component (such as alprostadil) and a cationic or positively charged vasoactive or erection-inducing component (such as prazosin) or a local anesthetic (such as lidocaine). These components are combined as acids and bases to form an organic salt or ionically bonded compound. The compounds have advantageous solubility characteristics and efficacy. A compound of the invention is combined with a pharmaceutical vehicle to form a composition which preferably includes an emulsifier. A local anesthetic and/or androgenic steroids may also be included. Compositions of the invention may also include more than one vasoactive organic salt compound. The composition can be advantageously formulated and administered to allow self-adjusted dosing, while minimizing or preventing overdosing.
Abstract: In accordance with the present invention, there are provided therapeutically effective compounds comprising an amphipathic carboxylate of the formula R—COOH, or a salt or an ester or amide of such compound, where R designates a saturated or unsaturated alkyl chain of 10-24 carbon atoms, one or more of which may be replaced by heteroatoms, where one or more of said carbon or heteroatom chain members optionally forms part of a ring, and where said chain is optionally substituted by a hydrocarbyl radical, heterocyclyl radical, lower alkoxy, hydroxyl-substituted lower alkyl, hydroxyl, carboxyl, halogen, phenyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkinyl)-substituted phenyl, C3-C7 cycloalkyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkinyl)-substituted C3-C7 cycloalkyl wherein said amphipathic carboxylate is capable of being endogenously converted to its respective coenzyme A thioester.
Type:
Application
Filed:
July 25, 2001
Publication date:
March 28, 2002
Applicant:
YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM
Abstract: Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the treatment of fibrotic lung disease, emphysema, and the prevention and treatment of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.
Abstract: A method of treating cancer with a pharmaceutical composition containing a pine root (Deutero Mycetes) fungal metabolite or an analog or derivative thereof.
Type:
Grant
Filed:
July 12, 1999
Date of Patent:
March 19, 2002
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Wei-Dong Jiang, Zhi-Dong Jiang, Rex T. Gallagher
Abstract: The present invention provides methods for treating intestinal fluid loss, whooping cough, anthrax, and conditions associated with smooth muscle contraction. The present invention also provides methods for inhibiting adenylate cyclase in vivo and in vitro.
Type:
Application
Filed:
May 19, 2001
Publication date:
March 14, 2002
Inventors:
Johnny W. Peterson, Deborah L. Gessell-Lee, Shamsher S. Saini
Abstract: The present invention is directed to methods for treating fibrosis related diseases and disorders, particularly scleroderma by treating a patient in need with a pharmaceutically efficacious amount of a prostacyclin derivative. The most preferred prostacyclin derivatives are cicaprost and iloprost.
Type:
Application
Filed:
July 25, 2001
Publication date:
March 7, 2002
Applicant:
Fibrogen, Inc.
Inventors:
Richard Stratton, Carol Black, George R. Martin, David F. Carmichael
Abstract: The present invention relates to a bioavailable pharmaceutical composition of 13-cis vitamin A acid (also known as 13-cis retinoic acid and isotretinoin) and a process for preparing the same. 13-cis vitamin A acid is a relatively water insoluble compound that degrades when exposed to light and atmospheric oxygen. Due to its instability and relative insolubility, the bioavailability of the drug after oral administration is difficult to achieve and has always been a challenge to a development pharmacist. It would therefore be desirable to provide a dosage form in which the drug is stable and predictably bioavailable.
Type:
Application
Filed:
April 9, 2001
Publication date:
February 28, 2002
Inventors:
Abha Pant, Inderdeep Bhatia, Sunilendu Bhushan Roy, Rajiv Malik
Abstract: An acidic aqueous hydrogen peroxid solution is provided, with improved disinfectant activity. Concentrated solutions preferably contain up to about 8% and as-used concentrations contain about 0.5% peroxide. The solution also contains from 0.1 to 5.0% of at least one acid compound, e.g. phosphoric and/or a phosphonate with from 1 to 5 phosphonic acid groups, and from 0.02 to 5% of at least one anionic surfactant. The surfactant is selected from C8 to C16-alkyl aryl sulphonic acids, sulphonated C12 to C22 carboxylic acids, C8 to C22-alkyl diphenyl oxide sulphonic acids, naphthalene sulphonic acids, C8 to C22 alkyl sulphonic acids, and alkali metal and ammonium salts thereof, and alkali metal C8 to C18 alkyl sulphates, and mixtures thereof. Most preferably the solution has an emulsifier, e.g. a salt of an alkylated diphenyl oxide. The solution may also contain corrosion inhibitors and/or lower alcohols.
Abstract: Disclosed are methods and compositions for reducing coronary artery stenosis, restoring blood flow to infarcted myocardium, improving myocardial perfusion, reducing heart attacks or other adverse cardiovascular events, or treating symptoms of inadequate myocardial function in a mammal involving administering to the mammal (a) a compound that includes eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol-lowering therapeutic, combined with dietary restrictions (resulting in aggressive loading of marine lipids), whereby a serum LDL concentration of less than 75 mg/dl (and preferably less than 55 mg/dl) is achieved. One particular method involves administering to the mammal a combination that includes (a) a compound that includes an eicosapentaeneoic or docosahexaeneoic acid (for example, a marine lipid) and (b) a cholesterol synthesis or transfer inhibitor, and which may also optionally include aspirin and/or niacin.
Abstract: An oral pharmaceutical dosage form including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaglandin and one or more excipients.
Type:
Application
Filed:
April 24, 2001
Publication date:
February 7, 2002
Inventors:
Austen John Woolfe, Gordon McIntyre, Nitin Vadilal Sheth
Abstract: A method and compound having betamethasone dipropionate and all-trans-retinoic is disclosed for the treatment of hair loss. The method also includes identifying any underlying conditions causing hair loss and administration of a salve of betamethasone dipropionate and all-trans-retinoic acid to the affected areas.
Abstract: The present invention relates to methods for stimulating bone formation in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype agonist.
Type:
Application
Filed:
July 3, 2001
Publication date:
January 10, 2002
Inventors:
Shun-Ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc Labelle, Kathleen Metters, Robert N. Young, Miron Weinreb
Abstract: Disclosed are skin care compositions containing retinoids which generally improve the quality of the skin, particularly human facial skin. More particularly, the present invention relates to retinol containing skin care compositions with improved skin compatibility.
Type:
Grant
Filed:
May 23, 1997
Date of Patent:
August 6, 2002
Assignee:
The Procter & Gamble Company
Inventors:
George Endel Deckner, James Pedrosa SaNogueira, Jr., Joseph Michael Zukowski